Vaccine Delivery Devices Market

Market Overview The global market for vaccine delivery devices is projected to expand significantly, rising from USD 7.92 billion in 2025 to USD 11.97 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 7.13%. These devices, including syringes, needles, jet injectors, and microneedle patches, are specialized medical tools used to administer immunobiological agents. This market growth is primarily driven by the increasing worldwide incidence of infectious diseases and extensive government-backed immunization campaigns focused on achieving universal coverage. The considerable need for these administration tools is evident in the large-scale procurements for global health programs; for instance, UNICEF supplied 886.19 million syringes globally for vaccination efforts in 2024, highlighting the essential role of scalable delivery systems in fulfilling public health objectives. Nevertheless, a major obstacle hindering market expansion is the complex issue of managing hazardous medical waste produced by single-use devices. The disposal of spent needles and syringes presents serious environmental and safety hazards, demanding sophisticated waste management infrastructure that often requires significant resources and is frequently inadequate in developing countries. As a result, the logistical and financial strains linked to ensuring safe disposal and preventing needle-stick injuries represent a critical impediment to the smooth distribution and uptake of traditional vaccine delivery methods, particularly in emerging markets. Market Driver Technological progress in microneedle and needle-free injection systems is fundamentally transforming the Global Vaccine Delivery Devices Market by overcoming logistical hurdles and enhancing patient adherence. These innovations, especially high-density microarray patches, remove the requirements for cold-chain storage and professional administration, making them highly suitable for deployment in resource-limited environments. This move towards less invasive solutions is attracting substantial investment to speed up their commercialization and increase manufacturing capacity. For instance, BioSpace reported in August 2025 that Vaxxas secured around AUD 90 million to advance its proprietary patch technology, indicating the industry's dedication to shifting from conventional needle-and-syringe methods to more scalable, user-friendly alternatives that boost immunological effectiveness. Simultaneously, the expansion of global immunization initiatives and governmental financial support serves as a key driver for market volume, stimulating the procurement of delivery devices to achieve universal health objectives. International organizations and national governments are intensifying efforts to vaccinate "zero-dose" children and combat preventable diseases through vigorous campaigns. The World Health Organization reported in July 2025 that global coverage for the first dose of the human papillomavirus (HPV) vaccine reached 31% in 2024, demonstrating a focused drive to broaden access to preventative care. To support these extensive programs, manufacturers are significantly expanding their production capabilities; for example, BD increased its domestic manufacturing capacity for safety-engineered injection devices by over 40% in January 2025 to meet the growing demands of the healthcare system. Market Challenge The efficient handling of hazardous medical waste produced by single-use vaccine delivery systems poses a significant obstacle to the growth of the Global Vaccine Delivery Devices Market. As immunization efforts expand to achieve universal coverage, the resulting increase in used syringes and needles creates a considerable logistical and financial bottleneck, especially in developing economies where adequate disposal infrastructure is often lacking. This shortfall compels healthcare systems to allocate vital funds toward waste treatment and containment rather than acquiring more delivery units, thus slowing market adoption and complicating supply chain operations. Moreover, the operational risks linked to this accumulation of hazardous materials directly impede the smooth distribution of traditional vaccine tools. The World Health Organization reported in late 2024 that out of approximately 16 billion injections administered globally, a substantial portion of the resulting sharps waste was not safely disposed of. This immense volume of bio-hazardous material introduces severe regulatory and safety liabilities, discouraging market penetration in regions with limited resources. Consequently, the inability to manage the entire lifecycle of these devices cost-effectively serves as a critical limitation, curbing the market's overall growth potential. Market Trends A significant emerging trend is the expansion of intranasal and mucosal vaccine delivery systems, driven by the necessity to build strong immunity at the initial sites of viral entry. Unlike conventional injectable vaccines that primarily offer systemic protection, these innovative mucosal platforms induce localized immune responses, such as IgA production in the respiratory and gastrointestinal tracts, which are crucial for preventing transmission. This shift is further propelled by the development of oral formats, which eliminate needle-phobia and simplify administration logistics. Confirming their effectiveness, Vaxart, Inc. reported in September 2025 that its second-generation oral vaccine candidates for norovirus demonstrated statistically significant increases in blocking antibodies of 141% and 94% against specific strains, underscoring the power of mucosal delivery. Concurrently, the increasing prevalence of prefilled syringes equipped with advanced safety features is transforming the manufacturing sector to prioritize scalability and quick deployment. This trend is marked by the adoption of Blow-Fill-Seal (BFS) technology, which combines device formation, filling, and sealing into one continuous process, thereby lowering contamination risks and simplifying supply chain complexities compared to glass alternatives. This transition supports the high-volume production required for global health directives while ensuring precise dosage. As an illustration of this industrial scaling, ApiJect Systems, Corp. announced in May 2025 a new strategic partnership to install manufacturing lines capable of producing approximately 250 to 300 million units annually, highlighting a substantial industry commitment to advanced prefilled solutions. Key Market Players * Becton Dickinson & Company * Bioject Medical Technologies, Inc. * PharmaJet, Inc. * Vaxxas, Inc. * Gerresheimer AG * SCHOTT AG * Corium, LLC * 3M Company * Croda International Plc * Meiji Holdings Co., Ltd. Report Scope In this report, the Global Vaccine Delivery Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Vaccine Delivery Devices Market, By Device * Syringes * Jet Injectors # Vaccine Delivery Devices Market, By Route Of Administration * Intradermal Vaccination * Intramuscular Vaccination * Subcutaneous Vaccination # Vaccine Delivery Devices Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Vaccine Delivery Devices Market. Available Customizations: Global Vaccine Delivery Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).